Health Care Select Sector SPDR Fund (XLV)…

Health Care Select Sector SPDR Fund (XLV)

170.70

+0.83 (0.49%)

as of Sep 25, 2026, 8:00:00 pm Market Open.

90 watching

BUY

Likes healthcare in general, a larger weight for him. Healthcare has been the leader YTD, only 11 days into the new year. The XLV would make sense for a broad-based, US healthcare strategy. IXJ is the global version of that.

PAST TOP PICK

(A Top Pick May 05/23, Down 7%)

Bought this to be defensive, however, health care wasn't that defensive this year. Now, HC is past seasonality and he doesn't like it.

BUY

The recent inflows into healthcare are based on the new diet drugs like Ozempic. Novo Nordisk and Eli Lilly have benefitted from this trend. These diet drugs are the AI equivalent in healthcare, are blockbusters.

COMMENT

Parts of healthcare are doing very well: equipment, disposables, more surgical procedures, managed care. Does this translate into stronger earnings and growth even during an economic contraction?

BUY

She picked it to start the year, but it hasn't performed well in the first six months. Healthcare has lagged this year, but when the VIX is this low, you want to hold defence.

BUY

She hopes healthcare picks up in the second half. She feels we're in late cycle where staples and utilities are expensive, but healthcare performs the best among these. HC has underperformed in the first half, but should improve second half or 2024, because XLV holds so many good companies.

BUY

She expects a recession in 2024, and higher unemployment. She sees a lot of opportunity in healthcare.

TOP PICK

Defensive name that provides exposure to health care sector.
Very strong sector as health care demand not going away.
Excellent prospects for healthcare during summer months.

BUY

She's not a fan of ETFs, this single-brushstroke style of investing, but an ETF makes sense in health care, because the companies are very different. Some will excel while others will flame out (considering their drug pipelines).

BUY

As a 5-year hold The valuation is attractive, balance sheet is good and there's non-discretionary demand for the products. Many of the underlying stocks pay a good dividend.

BUY

Is bullish biotech Biotchechs like Insight are up 13%, Moderna 25% and Regeneron 6% so hitting their lows. The whole XLV is up 8.5% off its June 17 low. 91 stocks in the S&P are above their 200-day moving average, and 18 of these are healthcare. This is the best sector to be overweight in.

BUY

Healthcare thrives when economies slow.

BUY

Allan Tong’s Discover Picks XLV ETF’s top holdings are Johnson & Johnson, UnitedHealth Group, Pfizer, Abbott Labs, AbbVie, Thermo Fisher, Merck, Eli Lilly and Danaher. A bullish case can be made for almost all all these names. Another plus: the MER is only 0.1%, though the dividend pays a lowly 1.4%. XLV’s PE is merely 6.62%, volumes average a healthy 14.8 billion a day, and its beta is a very stable 0.73. While you can make better gains holding some of the stocks this ETF holds, XLV is a safe way to play the American healthcare stocks in 2022. Read 3 Promising Healthcare Stocks for our full analysis.

BUY

He likes healthcare, given the return to preventative care and elective surgeries. Also, there's a strong pharma pipeline. Stay long in health.

BUY

Allan Tong’s Discover Picks However, if you want to own several in one place or can’t afford to buy one of these stocks individually, XLV is the place to go. It trades on the Nasdaq. It charges an ultra-low MER of 0.12%, trades at merely 4.18x PE and pays a 1.4% dividend. Also, average volumes are a robust 13.9 million and the Beta is a low 0.71. YTD, XLV has lost 7.55%, but Omicron was the major disruptor and restrictions are quickly lifting now. Essentially, you’re buying this ETF for the future. Read 3 Best Cyclical and Value ETFs for our full analysis.

Showing 16 to 30 of 69 entries

Most Recent Experts

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Kevin Simpson

Capital Wealth Planning

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Bruce Campbell (2)

Stone Castle Investment Management Inc.

Brendan Caldwell

Caldwell Securities

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at : [email protected].

Health Care Select Sector SPDR Fund (XLV)